PMV Pharmaceuticals (PMVP) has gained nearly 19% in three months following encouraging clinical data for its lead drug rezatapopt, which achieved a 46% response rate in ovarian cancer patients. The company plans to submit an NDA in Q1 2027 and raised $50.8 million through a public offering to fund operations into Q1 2028.
PMVP
PMV Pharmaceuticals, Inc · NASDAQ
Sign up free to see this.
Mkt Cap
$67.9M
Volume
167.2K
52W High
$1.91
52W Low
$1.02
PE Ratio
—
Avg Vol
762.5K
As of 10/23/26
Div Yield
—
Beta
0.76
As of 10/23/26
Analysts
All ›Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
Sentiment
No sentiment yet
At least 5 tagged posts are needed.
How do you feel about PMVP?
Latest news
News ›Headlines link to the publisher. Not investment advice.
Board · 0 threads
Open board ›No threads yet
Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.
Analysts
All ›Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
Community
7 daysNo sentiment yet
Posts 24h
0
Replies 24h
0
Watchers
0
Board · $PMVP · 0 threads
Sign in to post on $PMVP
No threads yet
Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.